Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial

PURPOSE: Metastatic GI stromal tumor (GIST) is a life-threatening disease with no therapy of proven efficacy after failure of imatinib and sunitinib. Regorafenib is a structurally unique inhibitor of multiple cancer-associated kinases, including KIT and platelet-derived growth factor receptor (PDGFR...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: George, Suzanne, Wang, Qian, Heinrich, Michael C., Corless, Christopher L., Zhu, Meijun, Butrynski, James E., Morgan, Jeffrey A., Wagner, Andrew J., Choy, Edwin, Tap, William D., Yap, Jeffrey T., Van den Abbeele, Annick D., Manola, Judith B., Solomon, Sarah M., Fletcher, Jonathan A., von Mehren, Margaret, Demetri, George D.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Clinical Oncology 2012
विषय:
Original Reports
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3675695/
https://ncbi.nlm.nih.gov/pubmed/22614970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.39.9394
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन